Metformin selectively affects human glioblastoma tumor-initiating cell viability
暂无分享,去创建一个
G. Sambuceti | Roberto Würth | T. Florio | F. Barbieri | G. Filaci | C. Marini | M. Massollo | D. Fenoglio | G. Zona | A. Pattarozzi | A. Daga | Monica Gatti | R. Sirito | A. Parodi | A. Corsaro | Adirana Bajetto
[1] T. Florio,et al. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. , 2012, Drug discovery today.
[2] Yangde Zhang,et al. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.
[3] J. Menéndez,et al. Rejuvenating regeneration , 2012, Cell cycle.
[4] A. Trumpp,et al. The evolving concept of cancer and metastasis stem cells , 2012, The Journal of cell biology.
[5] A. Khurana,et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells , 2012, Cell cycle.
[6] Jing Wang,et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. , 2012, Cell stem cell.
[7] Yunhui Liu,et al. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells , 2012, Neuroscience Letters.
[8] B. Leber,et al. Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.
[9] A. Munkarah,et al. Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis , 2012, Journal of oncology.
[10] E. Reed,et al. CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival , 2012, Clinical & Experimental Metastasis.
[11] T. Florio,et al. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma , 2012, British journal of pharmacology.
[12] R. Versteeg,et al. Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer , 2012, Clinical Cancer Research.
[13] A. Paiva,et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line , 2012, BMC Cancer.
[14] R. Agarwal,et al. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation , 2012, Cell cycle.
[15] B. Martín-Castillo,et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts , 2012, Oncotarget.
[16] Sean J Morrison,et al. Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.
[17] V. Baladandayuthapani,et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer , 2012, British Journal of Cancer.
[18] D. Xiao,et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy , 2012, Cell Death and Disease.
[19] M. Derwahl,et al. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. , 2012, The Journal of clinical endocrinology and metabolism.
[20] T. Stokke,et al. Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties , 2011, PloS one.
[21] B. Martín-Castillo,et al. Metformin: Multi-faceted protection against cancer , 2011, Oncotarget.
[22] L. Platanias,et al. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications , 2011, Oncotarget.
[23] A. Ratto,et al. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets. , 2011, Biochemical pharmacology.
[24] Zhihui Liu,et al. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. , 2011, Oncology reports.
[25] M. Halatsch,et al. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP‐activated protein kinase with olanzepine and metformin? , 2011, British journal of pharmacology.
[26] A. Faggiano,et al. Diabetes and Cancer , 2011, Front. Endocrin..
[27] Roberto Würth,et al. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature , 2011, Journal of Neuroimmunology.
[28] Kevin Struhl,et al. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. , 2011, Cancer research.
[29] O. Chinot,et al. Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution , 2011, Annals of Surgical Oncology.
[30] B. Martín-Castillo,et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells , 2011, Breast Cancer Research and Treatment.
[31] M. Chamberlain. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas , 2010, Expert review of neurotherapeutics.
[32] R. Memmott,et al. Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.
[33] P. Lichter,et al. Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells , 2010, Clinical Cancer Research.
[34] B. Martín-Castillo,et al. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena , 2010, Cell cycle.
[35] L. Mutti,et al. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. , 2010, Current cancer drug targets.
[36] K. Struhl,et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.
[37] G. Eibl,et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. , 2009, Cancer research.
[38] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[39] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Gianluigi Zona,et al. Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors* , 2009, Journal of Biological Chemistry.
[41] Nahum Sonenberg,et al. The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase , 2008, Cancer Prevention Research.
[42] M. Pollak,et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.
[43] F. Minuto,et al. Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas , 2008, Clinical Cancer Research.
[44] Dong-Sup Lee,et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas , 2008, Laboratory Investigation.
[45] E. Holland,et al. Glioma Formation, Cancer Stem Cells, and Akt Signaling , 2008, Stem Cell Reviews.
[46] I. Ben-Sahra,et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.
[47] T. Iwama,et al. Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells* , 2008, Journal of Biological Chemistry.
[48] A. Ratto,et al. 17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment , 2008, Molecular Pharmacology.
[49] J. Rich,et al. Cancer stem cells in radiation resistance. , 2007, Cancer research.
[50] Shari Bolen,et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.
[51] K. Black,et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.
[52] L. Ricci-Vitiani,et al. Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.
[53] Yuri Kotliarov,et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.
[54] S. Majumdar,et al. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.
[55] A. Ganser,et al. Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium , 2005, Circulation.
[56] Dario R Alessi,et al. Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.
[57] Ugo Orfanelli,et al. Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.
[58] Cynthia Hawkins,et al. Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.
[59] D. Alessi,et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.
[60] P. Wallace,et al. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. , 1999, Journal of immunological methods.
[61] R. Wallace. High-throughput screening , 1998 .
[62] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[63] H. Grosse. [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.